MA51996A - Anticorps à domaine unique se liant à la neurotoxine tétanique - Google Patents

Anticorps à domaine unique se liant à la neurotoxine tétanique

Info

Publication number
MA51996A
MA51996A MA051996A MA51996A MA51996A MA 51996 A MA51996 A MA 51996A MA 051996 A MA051996 A MA 051996A MA 51996 A MA51996 A MA 51996A MA 51996 A MA51996 A MA 51996A
Authority
MA
Morocco
Prior art keywords
domain antibodies
tetanus neurotoxin
neurotoxin
tetanus
antibodies
Prior art date
Application number
MA051996A
Other languages
English (en)
Inventor
Smit Abraham Johannes De
Michaël Marie Harmsen
Original Assignee
Smivet B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smivet B V filed Critical Smivet B V
Publication of MA51996A publication Critical patent/MA51996A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA051996A 2018-03-13 2019-03-13 Anticorps à domaine unique se liant à la neurotoxine tétanique MA51996A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18161521 2018-03-13

Publications (1)

Publication Number Publication Date
MA51996A true MA51996A (fr) 2021-01-20

Family

ID=61691657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051996A MA51996A (fr) 2018-03-13 2019-03-13 Anticorps à domaine unique se liant à la neurotoxine tétanique

Country Status (10)

Country Link
US (2) US12054540B2 (fr)
EP (1) EP3765495A1 (fr)
JP (2) JP7857080B2 (fr)
CN (2) CN117964751A (fr)
AU (2) AU2019233603B2 (fr)
BR (1) BR112020018563A2 (fr)
MA (1) MA51996A (fr)
MX (2) MX2020009507A (fr)
WO (1) WO2019175250A1 (fr)
ZA (1) ZA202403355B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113248610B (zh) * 2021-05-14 2022-08-16 厦门柏慈生物科技有限公司 白细胞介素2结合分子、其衍生物、试剂盒及其生产方法和用途
AU2022287910A1 (en) * 2021-06-07 2023-12-14 Michael L. MARTINO Rapid recognition based diagnosis and treatment
CN117624360A (zh) * 2022-08-26 2024-03-01 南京融捷康生物科技有限公司 一种抗trem2的单域抗体及其用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
EP0698097B1 (fr) 1993-04-29 2001-08-16 Unilever N.V. Production d'anticorps ou de fragments fonctionnalises d'anticorps, derives des immunoglobulines a chaine lourde de camelidae
EP0739981A1 (fr) * 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
GB9914861D0 (en) 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
AUPS022802A0 (en) * 2002-01-31 2002-02-21 Macfarlane Burnet Institute For Medical Research And Public Health Limited, The Anti-viral compounds
AU2004245429A1 (en) 2003-06-10 2004-12-16 Farallone Holding Bv Binding peptides: methods for their generation and use
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
TWI404727B (zh) 2006-01-25 2013-08-11 荷蘭鹿特丹Ｅｒａｓｍｕｓ大學醫學中心 對偶基因排除
CA2706425A1 (fr) 2007-11-27 2009-06-04 Ablynx N.V. Procede d'obtention de produits de construction de polypeptide comprenant au moins deux anticorps a domaine unique
CN101386648B (zh) * 2008-09-25 2012-05-30 中国人民解放军军事医学科学院微生物流行病研究所 抗b型肉毒神经毒素中和性单克隆抗体、其制备方法及用途
AU2010267963B2 (en) * 2009-07-02 2015-09-24 Merz Pharma Gmbh & Co. Kgaa Neurotoxins exhibiting shortened biological activity
WO2011064382A1 (fr) 2009-11-30 2011-06-03 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre le virus syncytial respiratoire humain (hrsv) et polypeptides comprenant celles-ci pour la prévention et/ou le traitement d'infections du tractus respiratoire
SI3339323T1 (sl) * 2010-08-12 2019-12-31 Eli Lilly And Company Protitelesa proti N3PGLU amiloid beta peptidu in njihove uporabe
US9409950B2 (en) 2010-12-23 2016-08-09 Biogen Ma Inc. Linker peptides and polypeptides comprising same
JP6162135B2 (ja) * 2011-11-09 2017-07-12 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 短縮された生物活性を示す神経毒
WO2013110531A1 (fr) * 2012-01-23 2013-08-01 Ablynx Nv Séquences dirigées contre le facteur de croissance des hépatocytes (hgf) et polypeptides les comprenant pour le traitement de cancers et/ou de tumeurs
WO2013157105A1 (fr) * 2012-04-18 2013-10-24 公立大学法人大阪市立大学 Anticorps humain spécifique de mucine 5ac et son utilisation
US11976110B2 (en) 2013-06-28 2024-05-07 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells
US11897921B2 (en) 2014-12-09 2024-02-13 New York University Propeptide fusion comprising a mutated clostridium botulinum neurotoxin and a VHH domain
US10668147B2 (en) * 2015-03-25 2020-06-02 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Anti-CD89 cytotoxic complex
EP3297672B1 (fr) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Protéines trispécifiques de liaison et méthodes d'utilisation

Also Published As

Publication number Publication date
JP2024023268A (ja) 2024-02-21
US20220275066A1 (en) 2022-09-01
AU2019233603B2 (en) 2025-06-26
US12054540B2 (en) 2024-08-06
JP7857080B2 (ja) 2026-05-12
MX2020009507A (es) 2020-10-22
CN112135840B (zh) 2024-01-23
ZA202403355B (en) 2024-12-18
US20240376185A1 (en) 2024-11-14
MX2025004782A (es) 2025-05-02
JP2021516682A (ja) 2021-07-08
CN112135840A (zh) 2020-12-25
CN117964751A (zh) 2024-05-03
BR112020018563A2 (pt) 2020-12-29
EP3765495A1 (fr) 2021-01-20
AU2025234234A1 (en) 2025-10-09
WO2019175250A1 (fr) 2019-09-19
AU2019233603A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
MA51734A (fr) Anticorps se liant à gprc5d
MA53434A (fr) Anticorps anti-tigit
EP3512549A4 (fr) Anticorps se liant à cd3
EP3883970A4 (fr) Anticorps anti-b7-h3
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
MA42380A (fr) Anticorps se liant à tau
MA47268A (fr) Anticorps anti-gpc3
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
EP3423089A4 (fr) Anticorps anti-tigit
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
MA50352A (fr) Anticorps multispécifiques
MA43660A (fr) Anticorps anti-facteur xi de coagulation
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3617231A4 (fr) Anticorps anti-gpc-1
MA49289A (fr) Anticorps se liant à steap-1
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3596126A4 (fr) Nouveaux anticorps anti-trkb
EP4271712A4 (fr) Anticorps anti-hvem
MA45234A (fr) Anticorps anti-facteur xi de coagulation
EP3998286A4 (fr) Anticorps bispécifique symétrique tétravalent
MA56466A (fr) Anticorps anti-epha4
EP3831851A4 (fr) Anticorps anti-btla